A Novel Scoring System Based on the Level of HDL-C for Predicting the Prognosis of t-DLBCL Patients: A Single Retrospective Study
Table 1
Baseline characteristics of 46 t-DLBCL patients.
Characteristics, n ()
Total patients
FL/ DLBCL
MZL/DLBCL
Others/DLBCL
P value
46 (100.0)
NA
25 (54.3)
15 (32.6)
6 (13.0)
Age (median, range)
56, 33-74
0
58, 33-74
53, 39-73
56, 42-70
NS
< 60 years
29 (63.0)
15 (60.0)
9 (60.0)
5 (83.3)
NS
≥60 years
17 (37.0)
10 (40.0)
6 (40.0)
1 (16.7)
Gender
0
Male
25 (54.3)
14 (56.0)
8 (53.3)
3 (50.0)
NS
Female
21 (45.7)
11 (44.0)
7 (46.7)
3 (50.0)
Coexisted with DLBCL at diagnosis
28 (60.9)
0
14 (56.0)
11 (73.3)
3 (50.0)
NS
Association with DLBCL in morphologic features
0
Wholly transformed
15 (32.6)
8 (32.0)
2 (13.3)
5 (83.3)
0.008
Partially co-existed
31 (67.4)
17 (68.0)
13 (86.7)
1 (16.7)
Ann Arbor stage
0
I-II
11 (24.0)
4 (16.0)
7 (46.7)
0 (0.0)
NS
III
6 (13.0)
3 (12.0)
2 (13.3)
1 (16.7)
IV
29 (63.0)
18 (72.0)
6 (40.0)
5 (83.3)
B symptoms
24 (52.2)
0
15 (60.0)
6 (40.0)
3 (50.0)
NS
BM involvement
25 (32.6)
0
11 (44.0)
1 (6.7)
3 (50.0)
0.032
IPI risk group
0
Low
16 (34.8)
5 (20.0)
10 (66.7)
1 (16.7)
NS
Low intermediate
10 (21.7)
7 (28.0)
1 (6.7)
2 (33.3)
High intermediate
10 (21.7)
7 (28.0)
2 (13.3)
1 (16.7)
High
10 (21.7)
6 (24.0)
2 (13.3)
2 (33.3)
Elevated LDH, > 245 U/L
17 (37.0)
0
11 (44.0)
3 (20.0)
3 (50.0)
NS
Elevated 2 MG, > 2.2 mg/L
29 (63.0)
0
19 (76.0)
7 (46.7)
3 (50.0)
NS
Elevated CRP, > 3.0 mg/L
23 (50.0)
0
13 (52.0)
5 (33.3)
5 (83.3)
NS
Declined HDL-C, ≤1.04 mmol/L
22 (51.2)
3
11 (45.8)
9 (64.3)
3 (60.0)
NS
DLBCL, diffuse large B cell lymphoma; FL, follicular lymphoma; MZL, marginal zone lymphoma; NA, not available; NS, not significant; BM, bone marrow; IPI, International Prognostic Index; LDH, lactate dehydrogenase; 2 MG, β2 microglobulin; CRP, C-reactive protein; HDL-C, high density lipoprotein cholesterol.
